





PB0178

### **CERTIFICATE OF MAILING**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to the: Assistant Commissioner for Patents Washington, D.C. 20231.

Melissa Leck Type or print name Signature

May 3, 2002 Date

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

M. Shannon

Group Art Unit:

1645

Serial No.:

Filing Date:

Title:

January 30, 2002

Human POSH-Like Protein 1

REQUEST FOR A CORRECTED FILING RECEIPT TECH CENTER 1600/2900

**Assistant Commissioner for Patents** Office of Initial Patent Examination **Customer Service Center** Washington, D.C. 20231

RECEIVED

JUN 0 5 2002

Sir:

TECH CENTER 1600/2900

Please furnish the undersigned with a corrected filing receipt for the above-identified application. The correction required are as follows:

In the "Domestic priority as claimed by applicant" section, please make the following correction:

THIS APPLN CLAIMS BENEFIT OF 60/328,205 10/10/2001 AND IS A CONTINUATION-IN-PART OF 09/864,761 05/23/2001 Enclosed is a marked up copy of the Filing Receipt having a mailing date of April 15, 2002, along with a copy of the Declaration as filed on January 30, 2002. Any questions can be referred to the undersigned.

Respectfully submitted,

Stephen G. Ryan, 39,0/5 Attorney for Applicants/

Amersham Biosciences Corp. 800 Centennial Avenue P. O. Box 1327 Piscataway, NJ 08855-1327

Tel: (732) 457-8071 Fax: (732) 457-8463





# United States Patent and Trademark Office

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 2023

www.uspto.gov

 APPLICATION NUMBER
 FILING DATE
 GRP ART UNIT
 FIL FEE REC'D
 ATTY.DOCKET.NO
 DRAWINGS
 TOT CLAIMS

 10/061,201
 01/30/2002
 1645
 2028
 PB0178
 11
 47

47 6

Stephen G. Ryan Amersham Biosciences 800 Centennial Avenue Piscataway, NJ 08855



CONFIRMATION NO. 2093
FILING RECEIPT

RECEIVE (1990) 007864320\*

JUN 0 5 2002

**TECH CENTER 1600/2900** 

Date Mailed: 04/15/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

#### Applicant(s)


Mark Shannon, Livermore, CA:

## Domestic Priority data as claimed by applicant

THIS APPLN CLAIMS BENEFIT OF 60/328,205 10/10/2001 AND IS A C-I-P OF 09/864,761 05/23/2001

### Foreign Applications

PCT/US01/00663 01/30/2001 PCT/US01/00664 01/30/2001 PCT/US01/00665 01/30/2001 PCT/US01/00666 01/30/2001 PCT/US01/00667 01/30/2001 PCT/US01/00668 01/30/2001 PCT/US01/00669 01/30/2001 PCT/US01/00670 01/30/2001



If Required, Foreign Filing License Granted 04/11/2002

Projected Publication Date: 08/01/2002

Non-Publication Request: No

Early Publication Request: No

Title

Human POSH-like protein 1

**Preliminary Class** 

435

## LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

### **GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

#### **NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).